<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Diagnostics of non-Hodgkin's <z:hpo ids='HP_0002665'>lymphomas</z:hpo> has improved significantly over the last decades </plain></SENT>
<SENT sid="1" pm="."><plain>Predictors have been found and new biological therapies developed </plain></SENT>
<SENT sid="2" pm="."><plain>Rituximab, an antibody recognizing the CD20 B cell antigen, has proven to be of especially high clinical importance </plain></SENT>
<SENT sid="3" pm="."><plain>In a proportion of follicular <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, long responses are achieved with rituximab alone, without the adverse effects of cytotoxic agents </plain></SENT>
<SENT sid="4" pm="."><plain>On the other hand, combining rituximab with cytotoxic agents extends the non-diseased period and total survival period both in follicular and diffuse large B cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
</text></document>